Literature DB >> 26638144

Performance of 14 rubella IgG immunoassays on samples with low positive or negative haemagglutination inhibition results.

Daniela Huzly1, Ingeborg Hanselmann2, Dieter Neumann-Haefelin2, Marcus Panning2.   

Abstract

BACKGROUND: Rubella IgG testing is routinely done in prenatal care and seroepidemiological studies. Recently concern was raised that seropositivity rates were decreasing questioning vaccination policies. Manufacturers of rubella IgG assays and authors of seroepidemiological studies use different cut-offs for the definition of seropositivity. As rubella virus circulation is reduced since many years, seronegativity rates might be overestimated using an inappropriate cut-off.
OBJECTIVES: Using different cut-off definitions we compared fourteen current rubella IgG immunoassays for sensitivity and qualitative result concordance in samples with low positive or negative haemagglutination inhibition (HI) titre. STUDY
DESIGN: 150 clinical samples from patients and health care workers were included in the study. All samples were measured in 14 different rubella IgG immunoassays. Seropositivity was defined using recombinant rubella IgG immunoblot as reference standard.
RESULTS: The concordance of qualitative results using the manufacturers cut-off definitions was 56.4% if grey-zone results were analysed separately and 69.8% if grey-zone results were defined as positive. Using universal cut-offs of 10 IU/ml or 15 IU/ml the concordance was 70% and 61.4% respectively. Using the different cut-off definitions up to 71 out of the 124 immunoblot-positive samples tested negative in the immunoassays. The mean coefficient of variation (CV) of quantitative results in positive samples was 51% (range 19-113%).
CONCLUSIONS: Determination of rubella immunity by measurement of rubella-IgG in a population with high vaccination coverage with current assays leads to a high number of false negative results. The value of routine rubella antibody testing in countries with high vaccination coverage should be discussed.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Assay comparison; CRS; Rubella; Seroepidemiologic studies

Mesh:

Substances:

Year:  2015        PMID: 26638144     DOI: 10.1016/j.jcv.2015.11.022

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

1.  Assessing Immunity to Rubella Virus: a Plea for Standardization of IgG (Immuno)assays.

Authors:  Elise Bouthry; Milena Furione; Daniela Huzly; Adaeze Ogee-Nwankwo; LiJuan Hao; Adebola Adebayo; Joseph Icenogle; Antonella Sarasini; Maria Grazia Revello; Liliane Grangeot-Keros; Christelle Vauloup-Fellous
Journal:  J Clin Microbiol       Date:  2016-05-04       Impact factor: 5.948

2.  Where to Now for Standardization of Anti-Rubella Virus IgG Testing.

Authors:  Wayne Dimech
Journal:  J Clin Microbiol       Date:  2016-05-11       Impact factor: 5.948

3.  Pitfalls of rubella serology while on the brink of elimination: evaluation of national data, Belgium, 2017.

Authors:  Sofie Colman; Kris Vernelen; Bernard China; Dorien Van den Bossche; Laura Cornelissen; Marie-Luce Delforge; Marijke Reynders; Mario Berth; Melissa Depypere; Natasja Van Gasse; Sara Vijgen; Jos Van Acker; An Boel; Elizaveta Padalko
Journal:  Euro Surveill       Date:  2021-05

4.  Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.

Authors:  Iana H Haralambieva; Michael J Gibson; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

5.  Benefits and Challenges in Using Seroprevalence Data to Inform Models for Measles and Rubella Elimination.

Authors:  Amy K Winter; Micaela E Martinez; Felicity T Cutts; William J Moss; Matt J Ferrari; Amalie McKee; Justin Lessler; Kyla Hayford; Jacco Wallinga; C Jess E Metcalf
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

6.  Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey.

Authors:  Kyla Hayford; Simon Mutembo; Andrea Carcelen; Hellen K Matakala; Passwell Munachoonga; Amy Winter; Jane W Wanyiri; Kelly Searle; Francis D Mwansa; Angels Mwiche; Caroline Phiri; Chris Book; Philip E Thuma; William J Moss
Journal:  Vaccine       Date:  2019-03-21       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.